Edition:
United States

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,927.00GBp
12:04pm EDT
Change (% chg)

-27.50 (-0.56%)
Prev Close
4,954.50
Open
4,970.50
Day's High
4,977.50
Day's Low
4,916.50
Volume
1,696,461
Avg. Vol
3,020,509
52-wk High
5,505.00
52-wk Low
3,680.00

Select another date:

Wed, Mar 29 2017

BRIEF-AstraZeneca's autoimmune disease drug receives orphan designation

* Potential medicine for neuromyelitis optica spectrum disorder receives orphan designation in europe Source text for Eikon: Further company coverage: (Reporting By London Bureau)

BRIEF-Astrazeneca announced new results data evaluating cost-effectiveness of synagis

* Astrazeneca - announced new results data evaluating cost-effectiveness of synagis for respiratory syncytial virus in preterm infants 29-34 weeks gestational age

Chinese drug approval boosts AstraZeneca's lung cancer hopes

LONDON AstraZeneca has won approval for its lung cancer pill Tagrisso in China, a key market for the potential blockbuster medicine.

Chinese drug approval boosts AstraZeneca's lung cancer hopes

LONDON AstraZeneca has won approval for its lung cancer pill Tagrisso in China, a key market for the potential blockbuster medicine.

UPDATE 1-Chinese drug approval boosts AstraZeneca's lung cancer hopes

* First drug approved under Chinese priority review pathway (Adds further details on drug, executive comment)

AstraZeneca wins approval for lung cancer pill in China

LONDON, March 27 AstraZeneca said on Monday it had won approval for its lung cancer pill Tagrisso in China, a key market for the potential blockbuster medicine.

Circassia strikes deal with AstraZeneca for respiratory drugs

LONDON Britain's Circassia has secured the U.S. rights from AstraZeneca for two drugs to treat chronic obstructive pulmonary disease (COPD), a progressive lung condition affecting millions of people, for up to $230 million.

Circassia strikes deal with AstraZeneca for respiratory drugs

LONDON, March 17 Britain's Circassia has secured the U.S. rights from AstraZeneca for two drugs to treat chronic obstructive pulmonary disease (COPD), a progressive lung condition affecting millions of people, for up to $230 million.

UPDATE 1-AstraZeneca receives FDA setback for high potassium drug

LONDON, March 17 U.S. regulators have dealt a fresh blow to AstraZeneca's new medicine to treat high potassium levels, indicating it still has concerns over the manufacturing process of the drug.

AstraZeneca receives fresh blow to potassium drug

LONDON AstraZeneca said on Friday that U.S. regulators had rejected the British company's new drug for high potassium levels, in the latest setback to the product.

Select another date:

More From Around the Web